Level Biotechnology Inc. markets and distributes cell culture, immunology, and molecular biology products in Taiwan. More Details
Flawless balance sheet and good value.
Share Price & News
How has Level Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3118 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 3118's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 3118 underperformed the TW Healthcare industry which returned 11.9% over the past year.
Return vs Market: 3118 underperformed the TW Market which returned 48.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Level Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StSome Investors May Be Worried About Level Biotechnology's (GTSM:3118) Returns On Capital
2 months ago | Simply Wall StLevel Biotechnology Inc.'s (GTSM:3118) Stock Is Going Strong: Have Financials A Role To Play?
3 months ago | Simply Wall StCalculating The Fair Value Of Level Biotechnology Inc. (GTSM:3118)
Is Level Biotechnology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3118 (NT$31.35) is trading below our estimate of fair value (NT$108.72)
Significantly Below Fair Value: 3118 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3118 is good value based on its PE Ratio (14.8x) compared to the TW Healthcare industry average (16.8x).
PE vs Market: 3118 is good value based on its PE Ratio (14.8x) compared to the TW market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3118's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3118's PB Ratio (1.8x) is in line with the TW Healthcare industry average.
How is Level Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Level Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Level Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3118 has high quality earnings.
Growing Profit Margin: 3118's current net profit margins (9.8%) are higher than last year (7.5%).
Past Earnings Growth Analysis
Earnings Trend: 3118's earnings have declined by 7.7% per year over the past 5 years.
Accelerating Growth: 3118's earnings growth over the past year (44.5%) exceeds its 5-year average (-7.7% per year).
Earnings vs Industry: 3118 earnings growth over the past year (44.5%) exceeded the Healthcare industry -2.6%.
Return on Equity
High ROE: 3118's Return on Equity (12.5%) is considered low.
How is Level Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 3118's short term assets (NT$604.5M) exceed its short term liabilities (NT$197.4M).
Long Term Liabilities: 3118's short term assets (NT$604.5M) exceed its long term liabilities (NT$18.3M).
Debt to Equity History and Analysis
Debt Level: 3118 is debt free.
Reducing Debt: 3118 has not had any debt for past 5 years.
Debt Coverage: 3118 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 3118 has no debt, therefore coverage of interest payments is not a concern.
What is Level Biotechnology current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3118's dividend (3.19%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).
High Dividend: 3118's dividend (3.19%) is low compared to the top 25% of dividend payers in the TW market (5.01%).
Stability and Growth of Payments
Stable Dividend: 3118 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 3118 has only been paying a dividend for 8 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (61.3%), 3118's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Level Biotechnology has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Level Biotechnology Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Level Biotechnology Inc.
- Ticker: 3118
- Exchange: TPEX
- Founded: 1989
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: NT$1.017b
- Shares outstanding: 32.45m
- Website: https://www.level.com.tw
Number of Employees
- Level Biotechnology Inc.
- No. 80, Kangning Street
- Lane 169
- New Taipei City
Level Biotechnology Inc. markets and distributes cell culture, immunology, and molecular biology products in Taiwan. The company also engages in marketing and distribution of biomedical precision equipment...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 08:35|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.